Premier Research has continued its spate of acquisitions this year,
with the latest addition of clinical research organization (CRO)
Imform, which will aid the company's expansion plans into Eastern
India's Ranbaxy Laboratories has been granted a US patent on its
controlled-release drug delivery system, which takes the form of a
'floating' tablet that once swallowed, is retained in the upper
The European Commission has profiled the top 100 biotech technology
offers in a new brochure, which showcases the offers in such a way
that encourages European researchers to pursue the exploitation of
their own research results.
Omnicare will soon be offering staff that are "eClinical trained"
as a strategic tool to woo clinical trial contracts and compete
with services offered by rival contract research organizations
(CROs) such as Quintiles.
SRA International has received a $15 million outsourcing contract
from the National Institutes of Health (NIH) to provide enterprise
messaging and IT infrastructure support services over the next 6
Drug production company Patheon has released its fourth-quarter
results, which has revealed that profit has jumped 180 per cent
despite a recent production halt at a Puerto Rican subsidiary. This
bodes well for the recent manufacturing...
Shanghai-based biotech company WuXi PharmaTech has grown more than
100 times in the last 5 years after operating successfully in
China's infant biotech industry by providing variety of outsourcing
services in drug R&D.
Ventiv health reported a strong performance across all its business
units in the third quarter, with total revenues increasing by 44
per cent to $128.4 million (€107.6 million) compared to the third
quarter of 2004.
SR Pharma, specializing in RNAi therapeutics, will be the first
company to use the new UK National Biomanufacturing Centre (NBC),
operated by contract manufacturing organization (CMO) Eden
Biodesign, when it opens on schedule early...
Contract research organisations (CROs) are responding to the
looming threat of competition from India and China by moving
outside their traditional role of simply providing contract
services to drug companies.
Covalent Group has improved its financial position on last year,
reporting a net revenue increase of 45 per cent for the third
quarter of 2005 with sales of $2.7 million, (€2.3 million) compared
to $1.9 million one year ago.